

## Special Issue

# Herpesvirus-Specific Immunomonitoring in Patient Groups of Increased Risk

### Message from the Guest Editors

Herpesviruses may cause severe, even life-threatening disease in high-risk individuals, such as intensive care patients, HIV-infected people with AIDS, cancer patients, and in solid organ or bone marrow transplants. Mostly, severe diseases occur when the host's immunity is compromised due to aging, co-infections, or another underlying disease. Understanding the risk factors associated with a more severe course of the disease will help to improve prophylactic and therapeutic interventions against these viruses. We highly encourage the submission of articles to this Special Issue, which will contribute to a better understanding of the risk factors that are associated with a higher frequency of reactivations or a more severe disease. Furthermore, we accept manuscripts describing the herpesvirus-specific immunomonitoring in patient groups of increased risk. Identification of novel vaccine candidates or therapeutics, which can protect from disease or suppress the virus replication is important, articles on this topic are also welcome.

---

### Guest Editors

Prof. Dr. Oliver Witzke

Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, D-45147 Essen, Germany

Dr. Adalbert Krawczyk

Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, D-45147 Essen, Germany

---

### Deadline for manuscript submissions

closed (31 March 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/66968](https://mdpi.com/si/66968)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).